Mittie Doyle - 15 Jul 2024 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Chief Medical Officer
Signature
/s/ Donald R. Reynolds, by Power of Attorney
Issuer symbol
AVTX
Transactions as of
15 Jul 2024
Net transactions value
$0
Form type
4
Filing time
16 Jul 2024, 16:23:55 UTC
Previous filing
09 Aug 2023
Next filing
30 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTX Stock Option (Right to Buy) Award $0 +234,000 $0.000000 234,000 15 Jul 2024 Common Stock 234,000 $12.65 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the Option Shares vest on July 15, 2025 and the remainder of the Option Shares will vest in equal monthly installments over the following three (3) years, provided that Optionee remains an employee of the Company on each such vesting date.